http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 14 May 2026 16:01:15 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Earnings/Senti+Biosciences+%28SNTI%29+Misses+Q1+EPS+by+14c/26494314.html <p>Senti Biosciences (NASDAQ: SNTI) reported Q1 EPS of ($0.14). Revenue for the quarter came in at $10 thousand versus the consensus estimate of $0 .</p><p>For earnings history and earnings-related data on Senti Biosciences (SNTI) <a href="http://www.streetinsider.com/ec_earnings.php?q=SNTI">click here</a>.</p> http://www.streetinsider.com/Earnings/Senti+Biosciences+%28SNTI%29+Misses+Q1+EPS+by+14c/26494314.html Thu, 14 May 2026 16:01:15 -0400 SNTI http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html <p align="center"><em> Secured strategic financing </em><em>vehicle for up to $40 million </em><br/><br/><em>Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)</em><br/><br/><em>Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (Senti Bio), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.</p> http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html Thu, 14 May 2026 08:45:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html <p align="center"><em> Secured strategic financing </em><em>vehicle for up to $40 million </em><br/><br/><em>Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)</em><br/><br/><em>Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (Senti Bio), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.</p> http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html Thu, 14 May 2026 08:45:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html <p align="center"><em> Secured strategic financing </em><em>vehicle for up to $40 million </em><br/><br/><em>Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)</em><br/><br/><em>Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (Senti Bio), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.</p> http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html Thu, 14 May 2026 08:45:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html <p align="center"><em> Secured strategic financing </em><em>vehicle for up to $40 million </em><br/><br/><em>Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)</em><br/><br/><em>Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (Senti Bio), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.</p> http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html Thu, 14 May 2026 08:45:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html <p align="center"><em> Secured strategic financing </em><em>vehicle for up to $40 million </em><br/><br/><em>Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)</em><br/><br/><em>Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (Senti Bio), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.</p> http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html Thu, 14 May 2026 08:45:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html <p align="center"><em> Secured strategic financing </em><em>vehicle for up to $40 million </em><br/><br/><em>Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)</em><br/><br/><em>Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (Senti Bio), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.</p> http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html Thu, 14 May 2026 08:45:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html <p align="center"><em> Secured strategic financing </em><em>vehicle for up to $40 million </em><br/><br/><em>Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)</em><br/><br/><em>Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (Senti Bio), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.</p> http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html Thu, 14 May 2026 08:45:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html <p align="center"><em> Secured strategic financing </em><em>vehicle for up to $40 million </em><br/><br/><em>Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)</em><br/><br/><em>Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (Senti Bio), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.</p> http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html Thu, 14 May 2026 08:45:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html <p align="center"><em> Secured strategic financing </em><em>vehicle for up to $40 million </em><br/><br/><em>Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)</em><br/><br/><em>Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (Senti Bio), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.</p> http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html Thu, 14 May 2026 08:45:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html <p align="center"><em> Secured strategic financing </em><em>vehicle for up to $40 million </em><br/><br/><em>Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)</em><br/><br/><em>Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (Senti Bio), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.</p> http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Advancement+of+SENTI-202+Program+into+Pivotal+Phase/26490795.html Thu, 14 May 2026 08:45:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/FDA/Senti+Bio+receives+FDA+guidance+for+SENTI-202+registrational+trial/26490755.html <p>Senti Biosciences Holdings Inc. (NASDAQ: SNTI) announced completion of a Type B meeting with the U.S. Food and Drug Administration regarding its SENTI-202 therapy for relapsed/refractory acute myeloid leukemia. The company plans to proceed with a single-arm, multi-center registrational trial following the FDA guidance.</p> <p>The biotechnology company identified a specific donor characteristic, termed "Donor X," that correlates with improved efficacy outcomes. Patients receiving SENTI-202 manufactured from Donor X-derived NK cells achieved a 50% composite complete remission rate compared to 12.5% for those receiving therapy from non-Donor X cells in the Phase 1 trial.</p> <p>The Donor X attribute is found in approximately 50% http://www.streetinsider.com/FDA/Senti+Bio+receives+FDA+guidance+for+SENTI-202+registrational+trial/26490755.html Thu, 14 May 2026 08:40:16 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/FDA/Senti+Bio+receives+FDA+guidance+for+SENTI-202+registrational+trial/26490755.html <p>Senti Biosciences Holdings Inc. (NASDAQ: SNTI) announced completion of a Type B meeting with the U.S. Food and Drug Administration regarding its SENTI-202 therapy for relapsed/refractory acute myeloid leukemia. The company plans to proceed with a single-arm, multi-center registrational trial following the FDA guidance.</p> <p>The biotechnology company identified a specific donor characteristic, termed "Donor X," that correlates with improved efficacy outcomes. Patients receiving SENTI-202 manufactured from Donor X-derived NK cells achieved a 50% composite complete remission rate compared to 12.5% for those receiving therapy from non-Donor X cells in the Phase 1 trial.</p> <p>The Donor X attribute is found in approximately 50% http://www.streetinsider.com/FDA/Senti+Bio+receives+FDA+guidance+for+SENTI-202+registrational+trial/26490755.html Thu, 14 May 2026 08:40:16 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/FDA/Senti+Bio+receives+FDA+guidance+for+SENTI-202+registrational+trial/26490755.html <p>Senti Biosciences Holdings Inc. (NASDAQ: SNTI) announced completion of a Type B meeting with the U.S. Food and Drug Administration regarding its SENTI-202 therapy for relapsed/refractory acute myeloid leukemia. The company plans to proceed with a single-arm, multi-center registrational trial following the FDA guidance.</p> <p>The biotechnology company identified a specific donor characteristic, termed "Donor X," that correlates with improved efficacy outcomes. Patients receiving SENTI-202 manufactured from Donor X-derived NK cells achieved a 50% composite complete remission rate compared to 12.5% for those receiving therapy from non-Donor X cells in the Phase 1 trial.</p> <p>The Donor X attribute is found in approximately 50% http://www.streetinsider.com/FDA/Senti+Bio+receives+FDA+guidance+for+SENTI-202+registrational+trial/26490755.html Thu, 14 May 2026 08:40:16 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/FDA/Senti+Bio+receives+FDA+guidance+for+SENTI-202+registrational+trial/26490755.html <p>Senti Biosciences Holdings Inc. (NASDAQ: SNTI) announced completion of a Type B meeting with the U.S. Food and Drug Administration regarding its SENTI-202 therapy for relapsed/refractory acute myeloid leukemia. The company plans to proceed with a single-arm, multi-center registrational trial following the FDA guidance.</p> <p>The biotechnology company identified a specific donor characteristic, termed "Donor X," that correlates with improved efficacy outcomes. Patients receiving SENTI-202 manufactured from Donor X-derived NK cells achieved a 50% composite complete remission rate compared to 12.5% for those receiving therapy from non-Donor X cells in the Phase 1 trial.</p> <p>The Donor X attribute is found in approximately 50% http://www.streetinsider.com/FDA/Senti+Bio+receives+FDA+guidance+for+SENTI-202+registrational+trial/26490755.html Thu, 14 May 2026 08:40:16 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/FDA/Senti+Bio+receives+FDA+guidance+for+SENTI-202+registrational+trial/26490755.html <p>Senti Biosciences Holdings Inc. (NASDAQ: SNTI) announced completion of a Type B meeting with the U.S. Food and Drug Administration regarding its SENTI-202 therapy for relapsed/refractory acute myeloid leukemia. The company plans to proceed with a single-arm, multi-center registrational trial following the FDA guidance.</p> <p>The biotechnology company identified a specific donor characteristic, termed "Donor X," that correlates with improved efficacy outcomes. Patients receiving SENTI-202 manufactured from Donor X-derived NK cells achieved a 50% composite complete remission rate compared to 12.5% for those receiving therapy from non-Donor X cells in the Phase 1 trial.</p> <p>The Donor X attribute is found in approximately 50% http://www.streetinsider.com/FDA/Senti+Bio+receives+FDA+guidance+for+SENTI-202+registrational+trial/26490755.html Thu, 14 May 2026 08:40:16 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html <p align="center"><em>Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable MRD-negative complete remissions</em></p> <p align="center"><em>To further optimize SENTI-202 efficacy, the selection criteria for donors for all future manufacturing will include the “Donor X” phenotype</em></p> <p align="center"><em>Phase 1 clinical trial patients receiving SENTI-202 from Donor X-derived NK cells achieved a 50% composite CR (cCR) rate</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (“Senti http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html Thu, 14 May 2026 08:40:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html <p align="center"><em>Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable MRD-negative complete remissions</em></p> <p align="center"><em>To further optimize SENTI-202 efficacy, the selection criteria for donors for all future manufacturing will include the “Donor X” phenotype</em></p> <p align="center"><em>Phase 1 clinical trial patients receiving SENTI-202 from Donor X-derived NK cells achieved a 50% composite CR (cCR) rate</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (“Senti http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html Thu, 14 May 2026 08:40:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html <p align="center"><em>Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable MRD-negative complete remissions</em></p> <p align="center"><em>To further optimize SENTI-202 efficacy, the selection criteria for donors for all future manufacturing will include the “Donor X” phenotype</em></p> <p align="center"><em>Phase 1 clinical trial patients receiving SENTI-202 from Donor X-derived NK cells achieved a 50% composite CR (cCR) rate</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (“Senti http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html Thu, 14 May 2026 08:40:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html <p align="center"><em>Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable MRD-negative complete remissions</em></p> <p align="center"><em>To further optimize SENTI-202 efficacy, the selection criteria for donors for all future manufacturing will include the “Donor X” phenotype</em></p> <p align="center"><em>Phase 1 clinical trial patients receiving SENTI-202 from Donor X-derived NK cells achieved a 50% composite CR (cCR) rate</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (“Senti http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html Thu, 14 May 2026 08:40:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html <p align="center"><em>Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable MRD-negative complete remissions</em></p> <p align="center"><em>To further optimize SENTI-202 efficacy, the selection criteria for donors for all future manufacturing will include the “Donor X” phenotype</em></p> <p align="center"><em>Phase 1 clinical trial patients receiving SENTI-202 from Donor X-derived NK cells achieved a 50% composite CR (cCR) rate</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (“Senti http://www.streetinsider.com/Press+Releases/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html Thu, 14 May 2026 08:40:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html <p align="center"><em>Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable MRD-negative complete remissions</em></p> <p align="center"><em>To further optimize SENTI-202 efficacy, the selection criteria for donors for all future manufacturing will include the “Donor X” phenotype</em></p> <p align="center"><em>Phase 1 clinical trial patients receiving SENTI-202 from Donor X-derived NK cells achieved a 50% composite CR (cCR) rate</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (“Senti http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html Thu, 14 May 2026 08:40:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html <p align="center"><em>Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable MRD-negative complete remissions</em></p> <p align="center"><em>To further optimize SENTI-202 efficacy, the selection criteria for donors for all future manufacturing will include the “Donor X” phenotype</em></p> <p align="center"><em>Phase 1 clinical trial patients receiving SENTI-202 from Donor X-derived NK cells achieved a 50% composite CR (cCR) rate</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (“Senti http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html Thu, 14 May 2026 08:40:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html <p align="center"><em>Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable MRD-negative complete remissions</em></p> <p align="center"><em>To further optimize SENTI-202 efficacy, the selection criteria for donors for all future manufacturing will include the “Donor X” phenotype</em></p> <p align="center"><em>Phase 1 clinical trial patients receiving SENTI-202 from Donor X-derived NK cells achieved a 50% composite CR (cCR) rate</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (“Senti http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html Thu, 14 May 2026 08:40:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html <p align="center"><em>Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable MRD-negative complete remissions</em></p> <p align="center"><em>To further optimize SENTI-202 efficacy, the selection criteria for donors for all future manufacturing will include the “Donor X” phenotype</em></p> <p align="center"><em>Phase 1 clinical trial patients receiving SENTI-202 from Donor X-derived NK cells achieved a 50% composite CR (cCR) rate</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (“Senti http://www.streetinsider.com/Globe+Newswire/Senti+Biosciences+Holdings+Announces+Positive+FDA+RMAT+Meeting+on+Registrational+Clinical+and+CMC+Strategy+for+SENTI-202+in+RelapsedRefractory+AML%2C+Along+with+Important+Efficacy+and+Durability+Update/26490751.html Thu, 14 May 2026 08:40:00 -0400 A.06822034 A.50216794 O.20026344 O.50574504 SNTI